A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio. | A rival bidder has emerged to ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...

Before joining Moderna, Cronin spent close to 20 years at Ogilvy, working within its global healthcare department in ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. | Eli Lilly is expanding its menu of ...

Digging deeper into the BIO survey results, 94% of companies polled said they expect tariffs on the EU to drive up ...